A 65-year-old lady presented with decreased vision in her left eye (LE). Best corrected visual acuity (BCVA) was 1/20. Complete examination showed idiopathic juxtafoveal retinal telangiectasis associated with subretinal neovascularization and she was treated with intravitreal ranibizumab every month for three months in the LE. After four months, her BCVA increased to 3/10. Fluorescein angiography (FA) showed minimal leakage and optical coherence tomography (OCT) confi rmed absence of intra-or subretinal fl uid in the macula. Examinations were repeated monthly for another 12 months and showed no recurrence. Intravitreal ranibizumab showed promising results for subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis. A prospective study with large series of patients and controls may be necessary in order to determine the effectiveness of this treatment.
Introduction
Gass and Blodi 1 defi ned bilateral acquired retinal telangiectasis or perifoveal telangiectasia or type 2A telangiectasis as a rare retinal disease characterized by retinal thickening temporal to the fovea, right-angle venules, retinal pigment epithelial (RPE) hyperplastic plaques, and crystalline deposits. Bilateral acquired retinal telangiectasis can be divided into fi ve stages. The disease is usually becoming symptomatic through the sixth decade of life when complicated by subretinal neovascularization which is localized mostly subfoveally in stage 5 of the disease. [1] [2] [3] We report the outcome of treatment with 0.5 mg intravitreal ranibizumab in a patient with a subretinal neovascular membrane secondary to idiopathic juxtafoveal retinal telangiectasis.
Case history
A 65-year-old Caucasian lady presented to our clinic complaining of decreased vision in her left eye (LE). On presentation, best-corrected visual acuity (BCVA) was 10/10 in the right eye (RE) and 1/20 LE. Anterior segment examination was unremarkable in both eyes and intraocular pressures were within normal limits. Fundus biomicroscopy revealed in the right macula, slightly dilated right-angle veins with RPE hyperplasia beneath them ( Figure 1A ). In addition to these fi ndings, in the left macula there was subretinal hemorrhage ( Figure 1B) . The clinical appearance of the macular area of the LE was consistent with idiopathic juxtafoveal retinal telangiectasis complicated by subretinal neovascularization. Fluorescein angiography (FA) and optical coherence tomography (OCT) were performed and confi rmed the above diagnosis ( Figures 1C-D, 2, 3A) . OCT of the LE revealed the characteristic appearance of outer and inner retina having similar refl ectivity and an area temporal to the fovea with high refl ectivity corresponding to the temporal area of choroidal neovascularization (CNV) ( Figure 3A) , which was observed in the angiogram. After a discussion outlining the possible risks and benefi ts of the treatment, the patient was started on 0.5 mg intravitreal ranibizumab in the LE. Based on the fi ndings of FA and OCT which were performed monthly, the patient underwent three intravitreal injections of ranibizumab every month for three months. Following these injections, BCVA increased to 3/10 and both clinical and angiographic appearances showed signifi cant improvement with minimal leakage in FA and absence of intra-or subretinal fl uid in OCT and signifi cant reduction in retinal thickness; the RPE remained thickened (Figures 3B, 4A-B). Examinations were repeated monthly for another 12 months and showed no recurrence of CNV.
Discussion
Bilateral acquired retinal telangiectasis or retinal telangiectasis type 2A, according to Gass and Blodi, or type 2 perifoveal telangiectasia according to the classification by Yannuzzi is a symmetrical disease. 1, 3 The area involved is usually less than a disc diameter and is typically temporal to the fovea. 1 Gas and Blodi divided the development of group 2A telangiectasis into five stages. 1 Stage 1 is found on FA on the asymptomatic fellow eye as staining at the level of the RPE. 
Lucentis for CNV due to idiopathic telangiectasis type2A
Yannuzzi's classification of the disease, is associated with subretinal neovascularization. 1, 3 According to Engelbrecht and colleagues 2 the natural course of the disease in stage 5 is not good in 80% of cases, resulting to visual acuity of 1/20 or less.
Snyers and colleagues showed that from four patients treated with photodynamic therapy (PDT), three of those retained their visual acuity, however, there was no signifi cant improvement. 4 Vascular endothelial growth factor (VEGF) is a major key player for angiogenesis in the eye in several physiologic and pathologic conditions. Concerning anti-VEGF therapy in ocular disease, clinical trials with ranibizumab show a benefi cial effect for all subtypes of CNV including diseases such as pathological myopia and age-related macular degeneration. In addition, anti-VEGF therapy showed benefi cial results, both clinically and anatomically, for idiopathic macular telangiectasia which was not associated with subretinal neovascularization. 5 Recently, Ruys and colleagues have reported that the intravitreal delivery of bevacizumab (Avastin), with or without PDT was benefi cial for both anatomical and visual outcome for subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis. 6 Other reports also support this benefi cial outcome of bevacizumab (Avastin) ( Table 1) . [7] [8] [9] In most of these cases the neovascularization ceased after two injections of bevacizumab. 7 Also, combined PDT and intravitreal ranibizumab appears to be effi cacious in the treatment of subretinal neovascularization associated with proliferative type 2 idiopathic macular telangiectasia (Table 1) . 10 In our case we chose to use ranibizumab since it has been designed for intraocular use; three intravitreal applications of ranibizumab, repeated monthly, alone without any additional session of PDT, were suffi cient to cease the neovascularization during a follow-up time of 12 months.
In conclusion, intravitreal ranibizumab seems to have favorable results in the treatment of subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis. Further studies are required to evaluate the above fi ndings, although the implementation of large-series studies remains a challenge due to the rarity of cases with subretinal neovascularization secondary to idiopathic juxtafoveal retinal telangiectasis.
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